Ophthalmic Education:

Principles and Guidelines of a Curriculum for Education of the Ophthalmic Specialist: Appendix 1: Optic Neuritis Treatment Trial (ONTT)

On this page:

• Recommended Reading
  
  
• Additional Background Reading

Recommended Reading

Beck RW, Trobe JD. The Optic Neuritis Treatment Trial. Putting the results in perspective. The Optic Neuritis Study Group. J Neuroophthalmol 1995; 15: 131-135

Beck RW, Arrington J, Murtagh FR, Cleary PA, Kaufman DI. Brain magnetic resonance imaging in acute optic neuritis. Experience of the Optic Neuritis Study Group. Arch Neurol 1993; 50: 841-846

Beck RW, Cleary PA, Trobe JD et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med 1993; 329: 1764-1769

Beck RW, Cleary PA, Anderson MM Jr. et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992; 326: 581-588

(No authors listed). The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. 1997. Neurology 2001; 57(12 Suppl 5): S36-45

Fang JP. Lin RH. Donahue SP. Recovery of visual field function in the optic neuritis treatment trial. Am J Ophthalmol 1999; 128: 566-572

Trobe JD, Sieving PC, Guire KE, Fendrick AM. The impact of the optic neuritis treatment trial on the practices of ophthalmologists and neurologists. Ophthalmology 1999; 106: 2047-2053

(No authors listed). Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. The Optic Neuritis Study Group. Arch Ophthalmol 1997; 115: 1545-1552

(No authors listed). The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Neurology 1997; 49: 1404-1413

Cleary PA, Beck RW, Bourque LB, Backlund JC, Miskala PH. Visual symptoms after optic neuritis. Results from the Optic Neuritis Treatment Trial. J Neuroophthalmol 1997; 17: 18-23; quiz 24-8

Additional Background Reading

Keltner JL, Johnson CA, Spurr JO, Beck RW. Comparison of central and peripheral visual field properties in the optic neuritis treatment trial. Am J Ophthalmol 1999; 128: 543-55

Anderson MM, Boly LD, Beck RW. Remote clinic/patient monitoring for multicenter trials. Optic Neuritis Study Group. Control Clin Trials 1996; 17: 407-414

Rolak LA, Beck RW, Paty DW et al. Cerebrospinal fluid in acute optic neuritis: experience of the optic neuritis treatment trial. Neurology 1996; 46: 368-372

Trobe JD, Beck RW, Moke PS, Cleary PA. Contrast sensitivity and other vision tests in the optic neuritis treatment trial. Am J Ophthalmol 1996; 121: 547-553

Beck RW. The optic neuritis treatment trial: three-year follow-up results. Arch Ophthalmol 1995; 113: 136-137

Beck RW, Trobe JD. What we have learned from the Optic Neuritis Treatment Trial. Ophthalmology 1995;102: 1504-1508

Beck RW, Cleary PA, Backlund JC. The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Ophthalmology 1994;101: 1771-1778

Keltner JL, Johnson CA, Spurr JO, Beck RW. Visual field profile of optic neuritis. One-year follow-up in the Optic Neuritis Treatment Trial. Arch Ophthalmol 1994; 112: 946-953

Beck RW, Cleary PA. Optic neuritis treatment trial. One-year follow-up results. Arch Ophthalmol 1993; 111: 773-775

Beck RW, Cleary PA. Recovery from severe visual loss in optic neuritis. Arch Ophthalmol 1993; 111: 300

Beck RW, Diehl L, Cleary PA. Optic Neueritis Study Group: The Pelli-Robson Letter Chart: Normative data for young adults. Clin Vis Sci 1993; 8: 207-210

Beck RW, Kupersmith MJ, Cleary PA, Katz B. Fellow eye abnormalities in acute unilateral optic neuritis. Experience of the optic neuritis treatment trial. Ophthalmology 1993; 100: 691-697; discussion 697-698

Chrousos GA, Kattah JC, Beck RW, Cleary PA. Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial. JAMA 1993; 269: 2110-2112

Cleary PA, Beck RW, Anderson MM Jr. et al. Design, methods, and conduct of the Optic Neuritis Treatment Trial. Control Clin Trials 1993; 14: 123-142

Keltner JL, Johnson CA, Beck RW, Cleary PA, Spurr JO. Quality control functions of the Visual Field Reading Center (VFRC) for the Optic Neuritis Treatment Trial (ONTT). Control Clin Trials 1993; 14: 143-159

Beck RW. Corticosteroid treatment of optic neuritis: a need to change treatment practices. The Optic Neuritis Study Group. Neurology 1992; 42: 1133-1135

Beck RW. Optic Neuritis Study Group: The Optic Neuritis Treatment Trial: Implications for clinical practice. Arch Ophthalmol 1992; 110: 331-332

(No authors listed). The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. Arch Ophthalmol 1991; 109: 1673-1678

Beck RW. The Optic Neuritis Treatment Trial. Arch Ophthalmol 1988; 106: 1051-1053

Ma SL, Shea JA, Galetta SL et al. Self-reported visual dysfunction in multiple sclerosis: new data from the VFQ-25 and development of an MS-specific vision questionnaire. Am J Ophthalmol 2002; 133: 686-692

Ghosh A, Kelly SP, Mathews J, Cooper PN, Macdermott N. Evaluation of the management of optic neuritis: audit on the neurological and ophthalmological practice in the north west of England. J Neurol Neurosurg Psychiatry 2002; 72: 119-121

Beck RW. Comparison of the ONTT intravenous group and the CHAMPS placebo group. J Neuroophthalmol 2001; 21: 310

Long DT, Beck RW, Moke PS et al. The SKILL Card test in optic neuritis: experience of the Optic Neuritis Treatment Trial. Smith-Kettlewell Institute Low Luminance. Optic Neuritis Study Group. J Neuroophthalmol 2001; 21: 124-131

Hauser SL, Oksenberg JR, Lincoln R et al. Interaction between HLA-DR2 and abnormal brain MRI in optic neuritis and early MS. Optic Neuritis Study Group. Neurology 2000; 54: 1859-1861

Cole SR, Beck RW, Moke PS, Gal RL, Long DT. The National Eye Institute Visual Function Questionnaire: experience of the ONTT. Optic Neuritis Treatment Trial. Invest Ophthalmol Vis Sci 2000; 41: 1017-1021

Fang JP. Donahue SP. Lin RH. Global visual field involvement in acute unilateral optic neuritis.Am J Ophthalmol 1999; 128: 554-565

Arnold AC. Visual field defects in the optic neuritis treatment trial: central vs peripheral, focal vs global. Am J Ophthalmol 1999; 128: 632-634

Wakakura M, Minei-Higa R, Oono S et al. Baseline features of idiopathic optic neuritis as determined by a multicenter treatment trial in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG). Jpn J Ophthalmol 1999; 43: 127-132

Cole SR. Beck RW. Moke PS. Kaufman DI. Tourtellotte WW. The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis. Optic Neuritis Study Group. Neurology 1998; 51: 885-887

Phillips PH. Newman NJ. Lynn MJ. Optic neuritis in African Americans. Arch Neurol 1998; 55: 186-192

Schneck ME, Haegerstrom-Portnoy G. Color vision defect type and spatial vision in the optic neuritis treatment trial. Invest Ophthalmol Vis Sci 1997; 38: 2278-2289

Swartz NG, Beck RW, Savino PJ et al. Pain in anterior ischemic optic neuropathy. J Neuroophthalmol 1995; 15: 9-10

Wray SH. Optic neuritis: guidelines. Curr Opin Neurol 1995; 8:72-76

Arnold AC. Updated recommendations from the Optic Neuritis Treatment Trial. West J Med 1994; 161: 593-594

Trobe JD. High-dose corticosteroid regimen retards development of multiple sclerosis in optic neuritis treatment trial. Arch Ophthalmol 1994; 112: 35-36

Next: Appendix 1: Ischemic Optic Neuropathy Decompression Trial (IONDT)

Also see: Table of Contents of the Principles and Guidelines of a Curriculum for Education of the Ophthalmic Specialist